A. Garner support for patient and clinician access to all DMTs; continuation of therapy despite disease quiescence B. To substitute as guidelines for clinicians C. Both of the above D. To provide guidance on when to stop therapy in stable patients

A. Involving additional clinicians beyond the traditional healthcare team to help patients navigate financial, nutrition, and rehabilitation issues as well as any other non-MS symptoms that may arise, in a coordinated manner B. Involving non-MS specialists in a patient's care to solely manage any and all non-MS-related symptoms C. Collaborating with a pharmacist to only manage medication errors D. Updating additional clinician types involved in the care of a patient, only when a change occurs in the patient's MS treatment plan

A. Jen's MS will remain stable for the initial 2 months and then may worsen. B. Jen's adherence issues would be solved by offering her a generic version of her DMT. C. Jen's DMT should be switched because she is experiencing adherence issues. D. Jen's practitioner should also consider additional factors that may impact medication adherence such as route of delivery and tolerance to side effects.

A. Frequency of relapses and degree of disability B. Level of disability and ethnicity C. Risk tolerance and level of disability D. Risk tolerance and adherence

A. The practitioner should wait until her optic neuritis resolves and then start her on a DMT; in the interim a corticosteroid course should be started. B. The practitioner should start her on a DMT immediately. C. The practitioner should wait until another new lesion appears on the MRI. D. The practitioner should make certain the lesion is not associated with her migraines.